|Articles|June 10, 2020

Contagion Live News Network: Stenotrophomonas Clonal Group Shows Increased Biofilm Capacity

A summary of the latest infectious disease news.

Hello and welcome to Contagion. I’m assistant editor Grant Gallagher here with a brief on our top stories.

Stenotrophomonas maltophilia acquisition can lead to difficult respiratory issues for the immunocompromised. The multidrug-resistant opportunistic infection has increased in incidence within health care and community settings alike.

A team of European researchers have identified links between antibiotic resistant S maltophilia phenotypes and quorum sensing, a gene-regulation process which the bacterium can use to coordinate adaptations to host-cell environment. Results were published in Frontiers in Microbiology.

In other news, ImmunityBio continues to advance its Operation Warp Speed vaccine candidate in the hunt for a protective measure against SARS-CoV-2.

In an interview with Contagion, Dr. Patrick Soon-Shiong describes goals and expectations for the accelerated coronavirus vaccine program Operation Warp Speed.

Lastly, we featured an article from our print issue, providing pharmacist perspectives on Lefamulin. For these stories, and more infectious disease clinical coverage, visit Contagionlive.com. Thanks for listening.


Related to this article

New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.